Description: Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.
Home Page: www.aladdinid.com
Unter den Linden 10
Berlin,
10117
Germany
Phone:
49 30 700 140 449
Officers
| Name | Title |
|---|---|
| Mr. Wade Menpes-Smith | Chairman, CEO & MD |
| Mr. Bimal Shah | Deputy Chairman & COO |
| Mr. Hamish Badenoch | CFO & Director |
| Prof. David C. Rubinsztein | Member of Drug Discovery Advisory Board & Chief Scientific Advisor |
| Mr. Paul Sitoh | Head of Blockchain Technology |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.3271 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |